{"prompt": "['LIST OF TABLES', 'Table 1:', 'Measurement Locations to Determine Treatment Section Diameter', '9', 'Table 2:', 'Target STS Volume (mL) per Treatment Procedure', '13', 'Table 3:', 'Initial Positioning of The ClariVein Catheter and Dispersion Wire', '16', 'Table 4:', 'Characterization of Post-Ablation Superficial Thrombus Extension (PASTE)', '26', 'LIST OF FIGURES', 'Figure 1:', 'Catheter Assembly', '14', 'Figure 2: Motor Drive Unit', '15', 'Figure 3:', 'Catheter Assembly with Check Valve and Syringe', '15', 'Figure 4:', 'Connected catheter Assembly with MDU', '17', 'Figure 5:', 'Re-sheathing of Dispersion Tip', '20', 'Figure 6:', 'Fully Assembled ClariVein Device', '20', 'Page 65 of 101']['1.', 'INTRODUCTION', 'This VICARES Clinical Study Procedure Manual is an adjunct to the VICARESTM clinical study', 'protocol CL-001.', '1.1.', 'VICARES CLINICAL STUDY OVERVIEW', 'The VICARES is prospective, randomized, controlled, multi-center, double blind study of the', 'ClariVein RES for treatment of venous insufficiency associate with incompetent saphenous veins', 'due to superficial venous reflux in adults.', 'The VICARES clinical study is limited to the treatment of one incompetent saphenous', 'vein per treatment procedure.', 'Ancillary procedures will not be allowed per protocol until after completion of the', 'Week 12 post treatment follow-up visit.', 'Carefully read and understand the VICARES clinical study protocol CL-001, Investigator', 'Brochure, and this Procedure Manual.', 'Please contact the Sponsor or designated representative with any questions regarding the study', 'protocol, the study product, or any study related matter.', 'Page 66 of 101']['2.', 'STUDY PRODUCT AND CLINICAL SUPPLIES', '2.1.', 'Clinical Study Product', 'The study product, ClariVein RES, consists of STS solution and the ClariVein infusion delivery', 'system. Both STS and ClariVein will carry a label specifying: \"Caution: Limited by Federal (or', 'United States Law) to Investigational Use Only\".', '2.1.1.', 'STS Solution', 'STS will be provided as blinded supplies of STS solution (1% or 3%) in 2 mL ampules, packaged', 'in a carton of 5 ampules. Each carton will contain a total of 10 mL.', '2.1.2.', 'ClariVein', 'ClariVein infusion delivery system will not be blinded because it is not considered necessary to', 'maintain integrity of the study. Except for length, all models are identical. Physician will select', 'catheter model based on individual patient anatomy. Supplies of ClariVein (45, 65, or 85 cm', 'length model), packaged one per pouch in a shelf box of 5 pouches. The pouch contains a', 'covered tray holding: (1) Catheter assembly with check valve and Motor Drive Unit; and (1)', 'syringe, 5 mL (for sclerosant).', '2.1.3.', 'Other Clinical Supplies', 'Commercially available, commonly used vascular procedural accessories will be provided to the', 'investigational sites. These supplies are not being evaluated in this clinical study; therefore, they', 'will not be blinded and will not be labeled for investigational use. Accessory products may', 'include:', '(2) Pregnancy Kits', 'Sterile Procedure Accessories', '(1)', 'Vascular Access set with 0.018\" guidewire and 5 Fr Introducer', '(1)', 'Gauze Pad: 2\" X 2\"', '(1)', 'Gauze Pad: 4\" X 4\"', '(1)', '1 inch 30 G needle', '(2)', '1.5 inch 21 G filter needles (to draw up saline, and sclerosant)', 'Sterile Syringes:', '(1)', '3 mL syringe (for local anesthetic)', '(2)', '5 mL syringes (one for sclerosant, one for saline prime and flush)', 'Other Supplies', '(1)', 'Normal Saline (USP 0.9%) 10 mL Vial', '(1)', 'Local Anesthetic (lidocaine 1%)', '(4)', 'Writeable Syringe Labels', '(1)', 'Sterile Marking Pen', '(2)', 'Sterile Ultrasound Probe Cover', 'Page 67 of 101']\n\n###\n\n", "completion": "END"}